

H7 Hemagglutinin (HA) Protein from Influenza Virus, A/Canada/rv444/2004 (H7N3), Recombinant from Baculovirus

Catalog No. NR-12073

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor and Manufacturer:

St. Jude Children's Research Hospital (CEIRS)

Product Description:

H7 hemagglutinin (HA) protein from influenza virus A/Canada/rv444/2004 (H7N3)¹⁻³ is a full-length glycosylated recombinant protein that was produced in Sf9 insect cells using a baculovirus expression vector system.^{4,5} Recombinant H7 HA protein was purified under conditions that preserve its biological activity and tertiary structure.

Material Provided:

Each vial contains approximately 400 micrograms of purified recombinant H7 HA protein in PBS containing 0.05% Tween-20. The concentration, expressed as µg/mL, is shown on the Certificate of Analysis.

Packaging/Storage:

Purified recombinant H7 HA protein was packaged aseptically, in screw-capped plastic cryovials. This product is provided on refrigerated bricks and should be stored at 2°C to 8°C immediately upon arrival. Do not freeze.

Functional Activity:

NR-12073 is biologically active in a hemagglutination assay with 0.5% chicken red blood cells. NR-12073 is specific to the H7 HA subtype of influenza virus as determined in serological hemagglutination inhibition (HI) assays. NR-12073 demonstrates reactivity in HI and ELISA assays within the H7 HA subtype. Applications: HI, ELISA, SDS-PAGE, antiserum preparation (immunogen).

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: H7 Hemagglutinin (HA) Protein from Influenza Virus, A/Canada/rv444/2004 (H7N3), Recombinant from Baculovirus, NR-12073."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and

Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

NR-12073 is claimed in U.S. Patent Numbers 5,762,939 and 6,103,526, and the continuations, continuations-in-part, reissues and foreign counterparts thereof. Commercial use also requires a license from Protein Sciences Corporation, Meriden, Connecticut. For information call 203-686-0800.

References:

1. Hirst, M., et al. "Novel Avian Influenza H7N3 Strain Outbreak, British Columbia." Emerg. Infect. Dis. 10 (2004): 2192-2195. PubMed: 15663859.
2. Tweed, S. A., et al. "Human Illness from Avian Influenza H7N3, British Columbia" Emerg. Infect. Dis. 10 (2004): 2196-2199. PubMed: 15663860.

3. Pasick, J., et al. "Intersegmental Recombination between the Haemagglutinin and Matrix Genes was Responsible for the Emergence of a Highly Pathogenic H7N3 Avian Influenza Virus in British Columbia." J. Gen. Virol. 86 (2005): 727-731. PubMed: 15722533.
4. Smith, G. E., et al. Method for Producing Influenza Hemagglutinin Multivalent Vaccines Using Baculovirus. MG-PMC, LLC, assignee. U.S. Patent 5,762,939. 09 Jun. 1998.
5. Smith, G. E., et al. *Spodoptera frugiperda* Single Cell Suspension Cell Line in Serum-Free Media, Methods of Producing and Using. Protein Sciences Corporation, assignee. U.S. Patent 6,103,526. 15 Aug. 2000.

ATCC® is a trademark of the American Type Culture Collection.

